H.Res. 280: Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.

H.Res. 280: Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.

117th Congress · introduced 2021-03-26 · Foreign Trade and International Finance · Latest: Referred to the Subcommittee on Health.

federal

Follow this bill, step by step

Where it came from: introduced 2021-03-26 · official record
Who proposed it: Rep. Jackson, Ronny [R-TX-13] · what a sponsor is
What happened next: no floor votes in our records yet. Why?
Where it stands now: Referred to the Subcommittee on Health. Not final yet: this can still change. We check for updates every day.
If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.

Plain summary

This resolution commits to the use of competitive free market and free trade policies to combat national security threats caused by China and its attacks on the U.S. pharmaceutical manufacturing base. The resolution urges the United States to (1) remove tax, regulatory, and debt burdens and barriers that have weakened this base; (2) empower the U.S. Trade Representative to take specified actions to counter harmful and unfair trade practices by China; (3) address shortcomings in Food and Drug Administration data collection related to foreign-sourced pharmaceutical ingredients; and (4) identify and streamline regulatory hurdles that have impeded the U.S. pharmaceutical manufacturing base.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

A Yea supports adopting this resolution.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.

Source: Congressional Research Service summary (Introduced in House)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Jackson, Ronny [R-TX-13] · 14 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Jim Banks (R-IN), Scott Franklin (R-FL), Brian J. Mast (R-FL), James R. Baird (R-IN), Claudia Tenney (R-NY), Maria Elvira Salazar (R-FL), Tom McClintock (R-CA), Chip Roy (R-TX), Diana Harshbarger (R-TN), John R. Carter (R-TX), John H. Rutherford (R-FL), Victoria Spartz (R-IN)

Sponsor's campaign money: Rep. Jackson, Ronny [R-TX-13] reported raising $4.8 million (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Words on this page, explained (3)

Resolution: A formal statement or decision by a legislative body. Simple resolutions often only express an opinion or set rules for one chamber; they do not become law.
Roll-call vote: A vote where each member's position is recorded by name, so the public can see how every member voted. "Yea" means yes, "Nay" means no, "Present" means the member was there but did not take a side.
Securities: Financial investments that can be bought and sold, such as stocks and bonds.

Plain meanings written from linked sources. All words.

Sources

Congressional Research Service summary (Introduced in House)
Congress.gov
Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-117hres280.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/117/hres>

Record fed-us-cong117-hres280 · catalog fed-us-congress-bills-cong117 · updated 2026-11-15 by psicol fed-bills-cong117